HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

[Efficacy of specific immunotherapy in children with bronchial asthma, sensitised to dermatophagoides pteronyssinus]

AbstractThe aim of study was the evaluation of efficacy of specific immunotherapy using Alavac S HDM for 2-4 years in children with atopic bronchial asthma induced by Deramtophagoides pteronyssinus. The study was carried out in a group of 33 children aged 5-18 years, from the Outpatient Department of Immunology at the National Research Institute of Mother and Child. The children demonstrated clinical symptoms of asthma and had a medical history typical for this disease. Diagnostic procedures including skin prick tests and estimation of specific IgE to Dermatophagoides pteronyssinus by Pharmacia-CAP system gave positive results. The efficacy of therapy was monitored by a clinical score of symptoms with 0-10-20-30 points, recording symptoms relating to intensity of dyspneaa, wheezing, cough, value of PEF and concomitant medications for example corticoids and beta-antagonists. In the study group, 31 children (94%) with asthma treated by specific immunotherapy (AlavacS HDM) improved. This was confirmed by a statistically significant difference. The results indicate that specific immunotherapy is effective in the treatment of asthma in children sesitized to Dermatophagoides pteronyssinus.
AuthorsE Bulawa, M Wawrzyniak (Affiliation: Zaklad Immunologii, Instytut Matki i Dziecka, Kasprzaka 17a, 01-211, Warszawa, Poland. imid at imid.med.pl)
JournalMedycyna wieku rozwojowego (Med Wieku Rozwoj) 2000 Oct-Dec Vol. 4 Issue 4 Pg. 355-62 ISSN: 1428-345X [Print] Poland
Vernacular TitleSkuteczność immunoterapii swoistej u dzieci chorych na asthme oskrzelowa, uczulonych na roztocza kurzu domowego.
PMID11228593 (Publication Type: English Abstract, Journal Article)
Chemical References
  • Alavac S
  • Anti-Allergic Agents
  • Antigens, Dermatophagoides
  • Bacterial Vaccines
  • Glycoproteins
Topics
  • Adolescent
  • Anti-Allergic Agents (therapeutic use)
  • Antigens, Dermatophagoides
  • Asthma (therapy)
  • Bacterial Vaccines (therapeutic use)
  • Child
  • Child, Preschool
  • Desensitization, Immunologic
  • Glycoproteins (immunology)
  • Humans
  • Immunotherapy
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Research Interface PRO additionally includes drill-down to evidence, articles by author, export to Excel, FDA Link and mobile subscription:
1 year subscription, $45.00 USD